This randomized phase 2 trial by multiple groups from France reported that 8 x 6.5 Gy scheme is feasible without deteriorating local control and with similar toxicity rates, as compared to the standard 4 x 13 Gy scheme in patients with large uveal melanomas. For the 32 patients in the study, the 2-year local recurrence-free survival rate without enucleation was 79% (95% confidence interval, 65%-96%), similar in both arms. At baseline, visual acuity by average logarithm value of the minimum angle of resolution was 0.68 and 0.70 in the standard and experimental arms, and at last follow-up 2 and 1.7, with mean differences of 1.44 and 1.01, respectively (P = .39).